Kulvinder Kochar Kaur*

Obstetrics and Gynaecology, Specialist Reproductive Endocrinology and Infertility Specialist, Scientific Director Cum Owner Dr Kulvinder Kaur Centre For Human Reproduction Punjab, India.

*Corresponding Author: Kulvinder Kochar Kaur, Obstetrics and Gynaecology, Specialist Reproductive Endocrinology and Infertility Specialist, Scientific Director Cum Owner Dr Kulvinder Kaur Centre For Human Reproduction Punjab, India.

Received: July 30, 2025; Published:August 18, 2025

Abstract

Having reviewed the different significant etiopathogenesis and role of Vitamin D/its Receptor and Allyl Isothiocyanate (AITC)", with Prospective Therapies Like L-Carnitine (LC), Nicotinamide Ribose (NR) Combination, as well as Apical Sodium Dependent Bile Acids Transporter (ASBT) or Volixibat and Silybin, probiotics, prebiotics, and synbiotics., role of Resveratrol’s Effects, natural products in the treatment of diabesity, inclusive of polyphenols along with flavonoids, dietary polyphenols, like resveratrol, curcumin, proteintyrosine phosphatase1 B ( PTP1B) inhibitors, plant terpenes (specifically monoterpenes), flavonoids (querceetin, kaempherol), ursolic acid, besides epigenetic modes of certain plant agents antidiabetic action, like nonflavonoid polyphenols like curcumin, tannins, lignans as well as resveratrol, or flavonoids like anthrocyanins, epigallocatechin gallate (EGCG), quercetin, naringin, rutin along with kaempherol, astragaloside IV and other prospective agents, knowledge of Hepatic Macrophages and association of dietary fatty acids and gut microbiota alterations with Gut-Liver Axis with Gut Microbiome Dysbiosis correlated non alcoholic fatty Acid liver disease (NAFLD) along with non alcoholic steatohepapititis ( NASH) alias metabolic dysfunction-associated steatosis liver disease (MASLD, alias NAFLD earlier) or MASH now, Curcumin Actions, role ofi) Obeticholic acid (OCA; Farsenoid X receptor [FXR] agonist) ii) Elafibranor (a Peroxisome Proliferator Activated Receptor [PPAR ] α as well as δ agonist) iii) cenicriviroc (CVC-a dual antagonist of C-C chemokine receptor (cenicriviroc CCR) types 2 as well as 5 iv) resmetriom (THR-β- agonist) as well as aramchol (stearoyl-Co A desaturase [SCD1 inhibitor Yet no clearcut answer is there for therapy of, NAFLD,NASH metabolic dysfunction-associated steatosis liver disease (MAFLD), MASH. Herewe further detail, which herbal, plant products evaluated might work in therapy of such disorder. Other than silymarin, curcumin and probiotics, prebiotics, and synbiotics not much efficacy was seen with other bioactive compounds evaluated globally.

Keywords: Metabolic dysfunction-associated steatosis liver disease (MASLD; Probiotics and Synbiotics; Curcumin; Silybin

References

1. Kulvinder Kochar Kaur., et al. “A Mini Review on Development of Newer Therapies for Non Alcoholic Fatty Acid Liver Disease with Emphasis on Vitamin D and its Receptor and Allyl Isothiocyanate (AITC)". Acta Scientific Nutritional Health 12 (2019): 1-5.
2. Kulvinder Kochar Kaur., et al. “An Update on Further Progression of NAFLD, NASH with Prospective Therapies Like L-Carnitine (LC), Nicotinamide Ribose (NR) Combination, as well as Apical Sodium Dependent Bile Acids Transporter (ASBT) or Volixibat and Silybin as Alternatives”. International Journal of Clinical and Medical Case Reports 3 (2020): 138.
3. Kulvinder Kochar Kaur., et al. “Have Probiotics and Synbiotics passed the test of time to be implemented in management of obesity and related metabolic disorders-a comprehensive review”. Advances in Obesity, Weight Management and Control 1 (2019): 21-28.
4. Kulvinder Kochar Kaur., et al. “Will Utilization of Resveratrol’s Effects be Practical in Multiple Chronic Inflammatory Diseasesand Autoimmune Diseases: A Detailed Review of its Immune Responses and Further Clinical Development in Humans in Future - ASystematic Review". Acta Scientific Microbiology 1 (2019): 14-23.
5. Kulvinder Kochar Kaur., et al. “Role of Natural Products in the Treatment of Diabesity with Mechanism of Action-A Small Communication". Acta Scientific Nutritional Health7 (2019): 140-142.
6. Kulvinder Kochar Kaur., et al. “A Comprehensive Review Explaining the Detailed Mechanism of Actions of Various Lentils Like Soyabeans, Chickpeas in Improving Insulin Resistance”. Acta Scientific Nutritional Health 4 (2019): 1-13.
7. Kulvinder Kochar Kaur., et al. “Importance of simultaneous treatment of obesity and diabetes mellitus: A sequelae to the understanding of diabesity-A review”. Journal of Obesity Open Journal 1 (2019): 1-10.
8. Kulvinder Kochar Kaur., et al. “Bioactive Compounds within Herbs and Spices Contributing to Anti Diabetic Action in Type2 Diabetes Mellitus (T2DM)A Short Communication". Acta Scientific Nutritional Health1 (2020): 88-92.
9. Kulvinder Kochar Kaur., et al. “Role of Polyphenols like Resveratrol in Cancer Prevention and Treatment-Especially in Combination with Other Polyphenols Like Quercetin-Detailed Mode of Action and Future Perspectives-A Systematic Review”. Acta Scientific Cancer Biology7 (2020): 13-20.
10. Kulvinder Kochar Kaur., et al. “Will Probiotics Provide the Answer for Therapy of Non-alcoholic Fatty Liver Disease (NAFLD)? – A Systematic Review”. Biochemistry and Physiology 9 (2020):
11. Kulvinder Kochar Kaur., et al. “Are we any close to unraveling the mechanism of interactions among susceptibility genes towards Type 1 Diabetes, Gut Microbiota Along with Environmental factors ,specifically early diet patterns-A Systematic Review”. Endocrinology and Surgical Endocrinology1 (2021).
12. Kulvinder Kochar Kaur., et al. “How do we apply advances in knowledge of Hepatic Macrophages in treating Liver Diseases especially non alcoholic fatty liver disease (NAFLD), non alcoholic steatohepapititis ( NASH), with the increasing incidence of Diabesity-A Systematic Review”. EC Endocrinology and Metabolic Research (2020).
13. Kulvinder Kochar Kaur., et al. “Mechanisms that associate extension of Nonalcoholic fatty liver diseases (NAFLD) to NASH (Nonalcoholic steatohepatitis) and further progressing to cirrhosis and Hepatocellular carcinoma (HCC) in addition to few proposed biomarkers for poor prognosis”. Journal of Gynecologic 16 (2021): 1-18.
14. Kulvinder Kochar Kaur., et al. “How can we optimize therapy of Non Alcoholic Fatty Acid Liver Disease-A Short Communication on role of Astragal side IV and other prospective agents”. Clinical Research and Clinical Case Reports3 (2021): 1-4.
15. Kulvinder Kochar Kaur., et al. “Intestinal Immune System in the Regulation of Obesity and Metabolic Syndrome-Therapeutic Implications-A Systematic Review". EC Clinical and Experimental Anatomy7 (2020): 07-22.
16. Kulvinder Kochar Kaur., et al. “An update on management of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepapititis-Is the time ripe for achieving resolution of NAFLD and NASH soon”. International Journal of Endocrinology Research 2 (2021): 44-60.
17. Kulvinder Kochar Kaur., et al. “The Association of Non Viral Liver Diseases from NAFLD to NASH to HCC with the Pandemic of Obesity ,Type 2 Diabetes, or Diabesity and Metabolic Syndrome –Etiopathogenetic Correlation along with Utilization for Diagnostic and Therapeutic Purposes-A Systematic review”. Journal of Endocrinology Research 2 (2021): 10-34.
18. Kulvinder Kochar Kaur. “Delivered a talk on 30^th September on ’Advantages and Limitations of utilizing Clostridium species as Probiotics-A Systematic Review” in a webinar held by Gastroenterology conference (2020).
19. Kulvinder Kochar Kaur., et al. “The association of dietary fatty acids and gut microbiota alterations in the development of neuropsychiatric diseases: A systematic review”. Journal of Obesity Open Journal 1 (2020): 19-45.
20. Kulvinder Kochar Kaur., et al. “Role of Adipocyte impairment in Heart Failure Induction in subjects that are obese along with prediabetes and overt Diabetes mellitus -A Systematic Review”. International Journal of Cardiology: Cardiovascular 2 (2021): 1-21.
21. Kulvinder Kochar Kaur., et al. “An update on the Association of Gut-Liver Axis with Gut Microbiome Dysbiosis Correlated NAFLD along with NAFLD- HCC with Potential Therapeutic Approaches: a systematic review”. Journal of Gastroenterology and Hepatology (2022).
22. Kulvinder Kochar Kaur., et al. “A Plethora of Actions of Curcumin –a magical agent for treatment of wide range of diseases varying from Neuroinflammatory disease (AD,PD)-IBD to DM and CVD,NAFLD,NASH Along with various Cancers-A Systematic Review”. Acta Scientific (2021).
23. Kulvinder Kochar Kaur., et al. “De Novo lipogenesis inhibitors: as the other innovative agents for therapy of metabolic diseases (obesity, NAFLD/ NASH, CVD)”. Advances in Obesity, Weight Management and Control 3 (2022): 78-93.
24. Kulvinder Kochar Kaur., et al. “Therapeutic Role of Curcumin on Glycemic Regulation, Lipid Parameters and Potential Benefits on Hyperandrogenemia - A Short Communication". Acta Scientific Nutritional Health 2 (2022): 1-4.
25. Kulvinder Kochar Kaur., et al. “An Update on the Therapeutic Potential of Herbal Preparations with regards to Molecular and Biochemical Mechanisms in the Management of Diabetes Mellitus :a Systematic Review”. World Journal of Advance Healthcare Research3 (2022): 1-17.
26. Kulvinder Kochar Kaur., et al. “An update on the etiopathogenesis of NAFLD including Organokines for early diagnosis and improvement of management and preventing early HCC development: A narrative review”. Liver Research Open Journal1 (2023): 18-41.
27. Kulvinder Kochar Kaur., et al. “Inventing the immunomodulatory action of Food Plants with utilization of Metabolomics: A Narrative Review”. Acta Scientific Nutritional Health 2 (2023): 1-4.
28. Kulvinder Kochar Kaur., et al. “An update on Targeting Gut Microbiota (GM) for Avoidance of Metabolic dysfunction associated steatohepatitis propagation to Hepatocellular Carcinoma-A Narrative Review”. MAR Clinical Case Reports 5 (2025):
29. Kulvinder Kochar Kaur., et al. “Melatonin as a Future prospective therapy for Nonalcoholic Fatty Liver Disease by targeting hepatic ferroptosis: -- A Short Communication”. Acta Scientific Gastrointestinal Disorders 5 (2025): 35-45.
30. Zeng XF., et al. “The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus”. Metabolism 161 (2024):
31. Yates AA., et al. “Serving as an ad hoc Working Group on a Framework for Developing Recommended Intakes for Dietary Bioactives Perspective: Framework for Developing Recommended Intakes of Bioactive Dietary Substances”. Advances in Nutrition 12 (2021): 1087–1099.
32. Lai JC., et al. “A patient-centered approach to dietary supplements for patients with chronic liver disease”. Hepatology Communications 8 (2025):
33. Tabaeian SP., et al. “Prevalence of Non-alcoholic Fatty Liver Disease in Iran: A Systematic Review and Meta-analysis”. Journal of Clinical and Experimental Hepatology 14 (2024):
34. Lichtenstein AH., et al. “Perspective: Design and Conduct of Human Nutrition Randomized Controlled Trials”. Advances in Nutrition 12 (2021): 4-20.
35. Sorkin BC., et al. “Editorial: Plant Foods and Dietary Supplements: Building Solid Foundations for Clinical Trials”. Frontiers in Nutrition 9 (2022):
36. Arksey H and O’Malley L. “Scoping studies: Towards a methodological framework”. International Journal of Social Research Methodology 8 (2005): 19-32.
37. Levac D., et al. “Scoping studies: Advancing the methodology”. Implementation Science 5 (2010):
38. Pollock D., et al. “How-to”: Scoping review?” Journal of Clinical Epidemiology 176 (2024):
39. Handu D., et al. “Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review”. Nutrients 3 (2025): 453.
40. Perazza F., et al. “Dietary Strategies to Modulate Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)”. Nutrients 11 (2025): 1906.
41. Kulvinder Kochar Kaur., et al. “Update on Etiopathogenesis of Type 1 Diabetes (T1D): Emphasis on part of Crosstalk of Gut Microbiome, Pancreatic Cells and Bystander Activation of Memory CD8⁺T cells with Mitochondrial Melatonergic Pathway: Treatment Repercussions-A Narrative Review”. Universal Library of Medical and Health Sciences1 (2023): 41-64.
42. Hou Y., et al. “Targeted Sodium Acetate Liposomes for Hepatocytes and Kupffer Cells: An Oral Dual-Targeted Therapeutic Approach for Non-Alcoholic Fatty Liver Disease Alleviation”. Nutrients 5 (2025): 930.

Citation

Citation: Kulvinder Kochar Kaur. “An Update of Bioactive Compounds for Therapy of Metabolic Dysfunction-Associated Steatosis Liver Disease (MASLD) -- A Short Communication".Acta Scientific Gastrointestinal Disorders 8.9 (2025): 11-22.

Copyright

Copyright: © 2025 Kulvinder Kochar Kaur. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.